Abstract
In clinical trials, mepolizumab reduced clinically significant exacerbations (CSEs) and maintenance oral corticosteroid (mOCS) use in patients with severe eosinophilic asthma (SEA); greater benefits were observed in patients with comorbid CRSwNP. Equivalent long-term real-world data would enhance this evidence.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
